lower expenses

Group revenue for the quarter fell 6.1% to $29 million from $30.9 million the preceding year,  due primarily to a decline of 14.1% in the specialty pharma principals segment in 2Q19 on the back of higher demand in 2Q18, ahead of products licensing renewa